Merck & Co., Inc. (MRK) — Stock Price, Chart & Analysis
Merck & Co., Inc. (MRK) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $317.57B and a trailing P/E ratio of 102.86. Over the past 52 weeks, MRK has traded between $77.58 and $135.05. Merck & Co., Inc. pays a dividend yielding 2.7%. View the live MRK chart, technical opinion, analyst ratings, fundamentals and latest news below.
Merck & Co., Inc. (MRK) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $317.57B |
| P/E ratio (TTM) | 102.86 |
| EPS (TTM) | $1.25 |
| Dividend yield | 2.7% |
| 52-week high | $135.05 |
| 52-week low | $77.58 |
| Beta | 0.21 |
| Avg. volume | 10.23M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Merck & Co., Inc. (MRK)
How much does one share of Merck & Co., Inc. cost?
As of the latest update, one share of Merck & Co., Inc. (MRK) trades at $100 (+0.00% today).
What is Merck & Co., Inc.'s market cap?
Merck & Co., Inc. has a market capitalization of approximately $317.57B.
What is Merck & Co., Inc.'s P/E ratio?
Merck & Co., Inc. has a trailing price-to-earnings (P/E) ratio of 102.86.
What is Merck & Co., Inc.'s earnings per share (EPS)?
Merck & Co., Inc.'s trailing twelve-month EPS is $1.25.
Does Merck & Co., Inc. pay a dividend?
Yes — Merck & Co., Inc. pays a dividend with a yield of 2.7% ($3.40 per share annually).
What is Merck & Co., Inc.'s 52-week trading range?
Over the past year, MRK has traded between $77.58 and $135.05.
What is the analyst price target for Merck & Co., Inc.?
The mean analyst price target for Merck & Co., Inc. is $136.65. This is informational only and not investment advice.
Latest Merck & Co., Inc. (MRK) news
- Merck (MRK) Could Be 3% Undervalued On Raised Outlook And Key Drug ApprovalsNews · Aug 7, 2026
- This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking ZoneNews · Aug 6, 2026
- Merck & Co’s Stock: Analyst Estimates & RatingsNews · Aug 6, 2026
- Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and MoreNews · Aug 7, 2026
- After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?News · Aug 6, 2026
- MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim dataNews · Aug 6, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live MRK dashboard…